Vitasora Health (VHL) Status Update summary

Business progress and market positioning

• Achieved significant growth in U.S. operations, focusing on value-based care, risk-sharing contracts, and remote patient monitoring for chronic conditions.

• Blue-chip client base includes publicly listed organizations, major healthcare providers, and partnerships with Evolent Health and The Physicians Alliance Corporation.

• Positioned to benefit from CMS mandates for value-based contracts by 2030 and a rapidly growing RPM market projected to reach USD $30b with an 11.2% CAGR.

• Entire operational team is U.S.-based, led by CEO Marjan Mikel with over 35 years of US health tech experience.

• Board and management have strong backgrounds in investment banking, M&A, healthcare, and technology.

Revenue and patient growth outlook

• Recurring revenue currently at $5.5 million, projected to reach $18 million by H2 next year, with a run-rate ARR of ~USD $18M by H2CY26.

• Existing client pipeline includes 70,000 new patients, with over 1.2 million potential patients from new clients.

• Current programs serve 6,500 patients, aiming for over 30,000 by next year, with 55 contracted clients.

• Forecasts 30% conversion of pipeline patients into revenue-generating programs.

• Revenue mix expected to be one-third risk/value-based, two-thirds fee-for-service, shifting further to risk.

Differentiation and client solutions

• Offers a turnkey, full-suite solution for chronic disease management, with unique strengths in respiratory care and a fully integrated virtual care model.

• Platform is CMS compliant, integrates with major EMRs, and optimizes clinical and revenue workflows.

• Clinic-in-cloud model enables direct billing to insurers and CMS, supporting both fee-for-service and value-based care.

• All services are billable under distinct CPT codes, supporting multiple care management programs.

• Strong client satisfaction has led to expanded contracts and increased patient volumes.